Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer

The underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes tumor diversity and accounts for variable disease progression, therapeut...

Full description

Bibliographic Details
Main Authors: Christen A. Khella, Gaurav A. Mehta, Rushabh N. Mehta, Michael L. Gatza
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Journal of Personalized Medicine
Subjects:
Online Access:https://www.mdpi.com/2075-4426/11/2/149
id doaj-2eff6104440d40babffc357a89ebff50
record_format Article
spelling doaj-2eff6104440d40babffc357a89ebff502021-02-20T00:04:18ZengMDPI AGJournal of Personalized Medicine2075-44262021-02-011114914910.3390/jpm11020149Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian CancerChristen A. Khella0Gaurav A. Mehta1Rushabh N. Mehta2Michael L. Gatza3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USARutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USARutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USARutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USAThe underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes tumor diversity and accounts for variable disease progression, therapeutic response, and clinical outcome. Recent advances in high-throughput proteogenomic profiling of tumor samples have resulted in the identification of novel oncogenic drivers, tumor suppressors, and signaling networks; biomarkers for the prediction of drug sensitivity and disease progression; and have contributed to the development of novel and more effective treatment strategies. In this review, we will focus on the impact of historical and recent advances in single platform and integrative proteogenomic studies in breast and ovarian cancer, which constitute two of the most lethal forms of cancer for women, and discuss the molecular similarities of these diseases, the impact of these findings on our understanding of tumor biology as well as the clinical applicability of these discoveries.https://www.mdpi.com/2075-4426/11/2/149genomicsproteomicsbreastovariancancer
collection DOAJ
language English
format Article
sources DOAJ
author Christen A. Khella
Gaurav A. Mehta
Rushabh N. Mehta
Michael L. Gatza
spellingShingle Christen A. Khella
Gaurav A. Mehta
Rushabh N. Mehta
Michael L. Gatza
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
Journal of Personalized Medicine
genomics
proteomics
breast
ovarian
cancer
author_facet Christen A. Khella
Gaurav A. Mehta
Rushabh N. Mehta
Michael L. Gatza
author_sort Christen A. Khella
title Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
title_short Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
title_full Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
title_fullStr Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
title_full_unstemmed Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
title_sort recent advances in integrative multi-omics research in breast and ovarian cancer
publisher MDPI AG
series Journal of Personalized Medicine
issn 2075-4426
publishDate 2021-02-01
description The underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes tumor diversity and accounts for variable disease progression, therapeutic response, and clinical outcome. Recent advances in high-throughput proteogenomic profiling of tumor samples have resulted in the identification of novel oncogenic drivers, tumor suppressors, and signaling networks; biomarkers for the prediction of drug sensitivity and disease progression; and have contributed to the development of novel and more effective treatment strategies. In this review, we will focus on the impact of historical and recent advances in single platform and integrative proteogenomic studies in breast and ovarian cancer, which constitute two of the most lethal forms of cancer for women, and discuss the molecular similarities of these diseases, the impact of these findings on our understanding of tumor biology as well as the clinical applicability of these discoveries.
topic genomics
proteomics
breast
ovarian
cancer
url https://www.mdpi.com/2075-4426/11/2/149
work_keys_str_mv AT christenakhella recentadvancesinintegrativemultiomicsresearchinbreastandovariancancer
AT gauravamehta recentadvancesinintegrativemultiomicsresearchinbreastandovariancancer
AT rushabhnmehta recentadvancesinintegrativemultiomicsresearchinbreastandovariancancer
AT michaellgatza recentadvancesinintegrativemultiomicsresearchinbreastandovariancancer
_version_ 1724260062274256896